Analysts See $1.48 EPS for Polaris Industries Inc. (PII); 2 Analysts Covering Trinity Biotech plc (TRIB)

January 17, 2018 - By Louis Casey

Among 4 analysts covering Trinity Biotech (NASDAQ:TRIB), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Trinity Biotech had 5 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Trinity Biotech plc (NASDAQ:TRIB) earned “Buy” rating by TH Capital on Wednesday, July 29. The firm has “Outperform” rating by Raymond James given on Thursday, September 3. The stock of Trinity Biotech plc (NASDAQ:TRIB) has “Hold” rating given on Friday, October 23 by Craig Hallum. The company was downgraded on Wednesday, October 5 by Stephens. See Trinity Biotech plc (NASDAQ:TRIB) latest ratings:

Analysts expect Polaris Industries Inc. (NYSE:PII) to report $1.48 EPS on January, 23.They anticipate $0.30 EPS change or 25.42% from last quarter’s $1.18 EPS. PII’s profit would be $92.56M giving it 21.60 P/E if the $1.48 EPS is correct. After having $1.46 EPS previously, Polaris Industries Inc.’s analysts see 1.37% EPS growth. The stock decreased 1.64% or $2.13 during the last trading session, reaching $127.9. About 522,268 shares traded. Polaris Industries Inc. (NYSE:PII) has risen 5.51% since January 17, 2017 and is uptrending. It has underperformed by 11.19% the S&P500.

Trinity Biotech plc acquires, develops, makes, and markets medical diagnostic products for the clinical laboratory and point-of-care divisions of the diagnostic market. The company has market cap of $122.80 million. The firm offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It currently has negative earnings. It also develops, makes, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.

The stock decreased 0.28% or $0.015 during the last trading session, reaching $5.315. About 15,768 shares traded. Trinity Biotech plc (NASDAQ:TRIB) has declined 52.33% since January 17, 2017 and is downtrending. It has underperformed by 69.03% the S&P500.

Investors sentiment decreased to 0.72 in Q3 2017. Its down 0.49, from 1.21 in 2017Q2. It fall, as 35 investors sold Polaris Industries Inc. shares while 152 reduced holdings. 46 funds opened positions while 89 raised stakes. 56.03 million shares or 4.63% less from 58.75 million shares in 2017Q2 were reported. Texas-based Callahan Ltd Liability Corporation has invested 0.19% in Polaris Industries Inc. (NYSE:PII). Apg Asset Mgmt Nv accumulated 105,628 shares or 0.02% of the stock. 15,737 were reported by Hilltop. Neuberger Berman Group Ltd Company reported 209,017 shares. Td Asset invested in 2,119 shares. Cubist Systematic Strategies Ltd Liability holds 39,643 shares. Legal And General Group Inc Public Limited Com accumulated 298,548 shares. 42,474 were accumulated by Texas Permanent School Fund. Geode Mngmt Llc holds 462,369 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0.01% invested in Polaris Industries Inc. (NYSE:PII) for 9,367 shares. 32,976 are owned by Rafferty Asset Management Ltd Llc. Cincinnati Ins invested in 125,000 shares. Commonwealth Equity Services holds 0.01% or 10,008 shares. Price T Rowe Assoc Incorporated Md has invested 0% of its portfolio in Polaris Industries Inc. (NYSE:PII). 35,955 were reported by Tudor Invest Corp Et Al.

Among 20 analysts covering Polaris Industries (NYSE:PII), 3 have Buy rating, 2 Sell and 15 Hold. Therefore 15% are positive. Polaris Industries had 84 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, January 3 by Wedbush. B. Riley & Co maintained Polaris Industries Inc. (NYSE:PII) rating on Wednesday, October 25. B. Riley & Co has “Neutral” rating and $118 target. The stock of Polaris Industries Inc. (NYSE:PII) has “Outperform” rating given on Tuesday, September 13 by Robert W. Baird. Wedbush maintained the shares of PII in report on Wednesday, January 27 with “Neutral” rating. RBC Capital Markets maintained it with “Outperform” rating and $80 target in Wednesday, January 27 report. SunTrust maintained the stock with “Hold” rating in Tuesday, October 24 report. On Monday, August 29 the stock rating was maintained by Citigroup with “Buy”. Stifel Nicolaus downgraded the stock to “Hold” rating in Thursday, April 14 report. Northcoast initiated the stock with “Buy” rating in Monday, October 12 report. As per Tuesday, November 21, the company rating was maintained by KeyBanc Capital Markets.

Polaris Industries Inc. designs, engineers, makes, and markets power sports vehicles worldwide. The company has market cap of $8.00 billion. It operates through four divisions: Off-Road Vehicles /Snowmobiles, Motorcycles, Global Adjacent Markets, and Other. It has a 40.17 P/E ratio. The firm provides ORVs, including all-terrain vehicles and side-by-side vehicles for recreational, military, and utility use; snowmobiles and technical riding gears; three-wheel motorcycles; and low emission, light duty hauling, passenger, commercial, and industrial vehicles.

Since August 31, 2017, it had 0 insider purchases, and 6 sales for $9.32 million activity. Homan Matthew J. sold $2.93M worth of stock. 8,000 shares were sold by Dougherty Michael D., worth $977,840. Another trade for 5,250 shares valued at $489,511 was made by Williams James P on Thursday, August 31. Eastman Stephen L. had sold 8,500 shares worth $1.01M. 20,000 shares were sold by BOGART STACY L, worth $2.44 million on Thursday, October 26.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts